ClinicalTrials.gg
Enrolling by invitationNCT04548804BREACH-ECGIUpdated Oct 27, 2023

Better Mechanistic Understanding of and Risk Stratification for Ventricular Tachyarrhythmias Through ECGI

An interventional study of ECG-Imaging in Ventricular Tachycardia, Ventricular Arrythmia and Ventricular Fibrillation, sponsored by Maastricht University Medical Center. Enrolling by invitation at 2 sites in Netherlands. Open to participants aged 18 Years and older. Per ClinicalTrials.gov, last updated 2023-10-27.

Sponsored by Maastricht University Medical Center · Not applicable, Interventional, and Basic science

How we know

From the registry’s dates

  • Primary completion was expected by Feb 2026, 9 months ago, but the record still lists the study as enrolling by invitation.

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Not applicable
Study type
Interventional
Enrollment
270
Allocation
Non-randomized
Ages
18 Years and older
Sex
All
01

Where this study stands

Counted across the records on this site · 2026-11-22

Among 34 studies in Tachycardia, Ventricular with a site in Netherlands — 10 open to participants now, 11 under way, none of them phase 3. Tachycardia, Ventricular · Netherlands.

Planned enrollment
10th of 19
270 · median 270
Started
2020
with 1 other
No phase
13 of 34
4 open now
Primary completion
2026-02
later than 1 of 10 live
Registered
21st of 34
by date
Lead sponsor
2 of 34
Maastricht University Medical Center

Among the 34 studies in Tachycardia, Ventricular with a site in Netherlands, this one is the 10th largest by planned enrollment of the 19 interventional ones that give a count, is one of 2 that started in 2020, is one of 13 with no phase, reaches primary completion later than 1 of the 10 other live ones, and was the 21st registered.

Tachycardia, Ventricular

452 studies on the registry are indexed under Tachycardia, Ventricular; 121 are open to participants now.

Browse Tachycardia, Ventricular studies →

Open to participants now

10 of the 34 studies in Tachycardia, Ventricular with a site in Netherlands are open now. Recruiting first, the newest first:

4 more — sign in →

All 10 open studies →

A study can be open while its sites in Netherlands have not opened yet or have stopped. Only those recruiting at a site in Netherlands →

Who these studies take

Of the 86 Tachycardia, Ventricular studies recruiting now, 67 (78%) set no upper age limit and 1 (1%) stops at 75 or younger; 7 take children under 18; 5 take healthy volunteers.

This study: 18 Years and older · all sexes · no healthy volunteers.

The full table on the hub →

This tab as a report to print or save as PDF → With an account.

Was this useful?
Get alerts for this landscapeDownload CSVNarrow it in search →With an account: a weekly mail of what changed among 34 studies in Tachycardia, Ventricular with a site in Netherlands, or all of them as a file.
02

Study summary

This study aims to evaluate the electrophysiological properties of the heart conduction system in patients with (increased risk of) ventricular tachyarrhythmias (VTA) and sudden cardiac arrest, and in a control cohort. The electrophysiological properties will be measured with the relatively new technique ECG-Imaging (ECGI). Moreover, clinical data of subjects will be gathered.

By combining the data from the data gathering and the results of ECGI, the investigators hope to increase mechanistic understanding of and risk stratification for VTAs. The investigators aim to be able to identify patients at risk of an arrhythmic event, and aim for better treatment strategies in the future.

Read the detailed description

ECGI combines electrical body-surface mapping with 256 electrodes placed on the thorax with a CT-scan obtaining the anatomy of the heart and torso, hereby able to reconstruct local electrograms, activation and recovery times. In recent research, ECGI provided numerous extra insights into normal cardiac electrophysiology, but also electrophysiological disorders and disease. The results strongly suggest that ECGI can play a pivotal role in further characterizing arrhythmia mechanisms, therefore could do so for VTAs, leading to diagnosis and treatment improvement. Moreover, ECGI seems to have the potential to detect arrhythmogenic substrate in individuals before their first event, offering the possibility to diagnose and treat patients before sudden cardiac arrest occurs.

In the BREACH-ECGI study:

ECGI will be used to noninvasively characterize the epicardial electrophysiological substrate and triggers of:

  • Patients with (increased risk of) VTAs
  • A control cohort. Results will be evaluated for increased mechanistic understanding and risk stratification.

Moreover, clinical data of subjects will be gathered. These data will be analyzed to determine their prognostic value in terms of arrhythmia risk

03

Conditions studied

  • Ventricular Tachycardia
  • Ventricular Arrythmia
  • Ventricular Fibrillation
  • Polymorphic Ventricular Tachycardia
  • Sudden Cardiac Death
  • Sudden Cardiac Arrest
  • Sudden Cardiac Death Due to Cardiac Arrhythmia
  • Heart Arrest
  • Cardiac Death
  • Cardiac Arrest
  • Cardiac Arrhythmia
  • Congenital Heart Disease
04

Who can participate

Ages eligible
18 Years and older
Sexes eligible
All
Accepts healthy volunteers
No

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

In order to be eligible to participate in this study, a subject must be ≥ 18 years old, have either a history of VTAs or be at risk of VTAs and have one of the following diagnoses:

  • Ischemic cardiomyopathy
  • Non-ischemic cardiomyopathy
  • Non-structural heart disease
  • Congenital heart disease (with a limitation to CCTGA and situs inversus)

Or: a subject must be ≥ 18 years old and have a structurally normal heart with a clinical indication for a cardiac CT.

Exclusion criteria

Exclusion Criteria:

A potential subject who meets any of the following criteria will be excluded from participation in this study:

  • A known strong reaction against electrode attachment or contrast agent.
  • Any serious medical condition, which in the opinion of the investigator, may adversely affect the safety and/or effectiveness of the participant or the study.
  • Pregnancy, nursing or planning to be pregnant.
  • The subject has an estimated (eGFR) of \<30mL/min/1.73m2, using the MDRD calculation 14.
  • Being unable to give .
Terms in these criteria, in plain language(2)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

GFR and eGFR (kidney filtering)

GFR (glomerular filtration rate) is how much blood the kidneys filter each minute. It is usually estimated from a blood test — eGFR, by formulas such as CKD-EPI or MDRD — and some studies ask for it to be measured directly instead. Usually given in mL/min/1.73 m².

Check the method, the units and the minimum the study states. A value of 90 or above is in the normal-or-high range, but kidney damage can show in other tests too.

Informed consent

Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.

You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.

05

Study design

Phase
Not applicable
Primary purpose
Basic science
Allocation
Non-randomized
Intervention model
Parallel assignment
Masking
Single (Care provider)
Enrollment
270 participants (estimated)

Study arms

  • Experimental
    Control

    Control subjects receiving body-surface potential mapping (BSPM) and either a CT-scan or a CMR scan

    Diagnostic Test: ECG-Imaging

  • Experimental
    Diseased

    Diseased subjects receiving body-surface potential mapping (BSPM) and either a CT-scan or a CMR scan. Outcome measures from these procedures will be compared to controls.

    Diagnostic Test: ECG-Imaging

Interventions

  • Diagnostic testECG-Imaging

    A body surface potential mapping and a cardiac + low dose CT-scan

06

What researchers measure

Primary outcomes

  1. ECG-Imaging outcome: epicardial potentials

    reconstructed epicardial potentials, represented in mV over time(s).

    Time frame: 3 years

  2. ECG-Imaging outcome: activation and repolarization maps

    Activation and repolarization maps. Acivation and repolarization times are determined from the epicardial potentials, expressed in ms. These are shown on a CT-derived or CMR-derived heart mesh. The entire activation and repolarization of the epicardium of the heart can be visualized this way.

    Time frame: 3 years

Secondary outcomes

  1. (Possible) Prognostic risk factors for recurrent ventricular arrhythmias

    Possible risk factors, found in the clinical data collection, expressed as odds/hazard ratio.

    Time frame: 6 years

  2. Recurrence of ventricular arrhythmias

    Documentation over the period of follow-up, if subjects had a recurrence of ventricular arrythmia(s), presented as number of events over a time period.

    Time frame: 6 years

07

Study locations

2 sites
08

References and documents

Individual participant data

Plan to share: Undecided

No publications or documents are linked to this record.

09

Timeline

Tracking since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reachedSimilar studies: half by the dot; the band is the middle halfHalf of similar studies reached it by the dot; the band is the middle half, from a quarter to three quarters

Started Jun 2020 (actual). Primary completion is estimated for Feb 2026, 68 months after the start.

Of 86 non-industry interventional studies with no phase under Tachycardia, Ventricular, half reached primary completion within 37 months of starting (the median), counting those still running; a quarter within 25 and three quarters within 70. This study's planned 68 months is above that.

Counting every sponsor, half of 126 studies reached it within 36 months; a quarter within 20 and three quarters within 66.

How these figures are worked out, and which studies are left out of them.

Registered
Sep 8, 2020
First posted
Sep 16, 2020
StartActual
Jun 10, 2020
Primary completionEst.
Feb 12, 2026
CompletionEst.
Feb 12, 2026
Last update
Oct 27, 2023
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
No changes since tracking began. The registry record was last updated on Oct 27, 2023, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
10

Registry details

Key details

Study ID
NCT04548804
Collaborators
Jessa Hospital
Responsible party
Sponsor
First posted
Sep 16, 2020
Start date
Jun 10, 2020
Primary completion
Feb 12, 2026 (estimated)
Completion
Feb 12, 2026 (estimated)
Last update
Oct 27, 2023

Oversight

Data monitoring committee
Yes
FDA-regulated drug
No
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Interested in this study?

Eligibility is decided by the study team. Share this record with your doctor or contact the team directly.

No contact was published for this record. The registry link below has the sponsor’s details.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Start the discussion